BioMarin: Q3 Earnings Snapshot
BioMarin Pharmaceutical Inc. reported a Q3 loss of $122.8 million, or 63 cents per share, but adjusted earnings of 23 cents per share beat expectations. Revenue of $1.02 billion missed forecasts. The company expects full-year earnings of $2.80 to $3.10 per share and revenue of $3.8 billion to $3.9 billion. Shares are down 3% YTD but up 7% over 12 months.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger short‑term price declines, but long‑term valuation hinges on clinical trial outcomes.
Market read
The report provides fresh earnings data that can influence trading decisions on BMRN and related biotech stocks.
What to watch
Guidance range remains relatively strong; upcoming trial data could offset short‑term earnings disappointment.
Background
BioMarin is a rare‑disease biopharma with a pipeline of gene‑therapy candidates.
Ticker impact
BioMarin reported Q3 loss of $122.8M, 63c per share loss versus 9c expected, revenue $1.02B, and FY guidance $2.80-$3.10 EPS.
downside pressure as market prices in worse-than-expected loss and revenue miss
The loss per share was significantly larger than analyst expectations, and revenue fell short, which typically triggers a sell-off.
Market effects
Biotech sector may see broader weakness as earnings miss highlights challenges in rare‑disease pipelines.
U.S. biotech stocks could face short‑term pullback on the Nasdaq.
Limited to investors tracking U.S. biotech earnings; minimal global macro effect.
Counterpoint
If the loss is driven by one‑time items, the stock may be oversold and could rebound on future pipeline milestones.
Key entities
- companyBioMarin Pharmaceutical Inc.
U.S. listed biotech reporting Q3 results.
